NCT03738475 - Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 11, 2018

Primary Completion Date

June 24, 2019

Study Completion Date

July 22, 2019

Conditions

Celiac Disease

Interventions

DRUG

TIMP-GLIA

8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8.

DRUG

Placebo

Administered intravenously on days 1 and 8.

Trial Locations (8)

Jacksonville Center for Clinical Research, Jacksonville

Rapid Medical Research, Beachwood

Indianapolis Gastroenterology Research Foundation, Indianapolis

Prism Clinical Research, Saint Paul

Mayo Clinic, Rochester

Advanced Clinical Research, Meridian

Advanced Clinical Research, West Jordan

Beth Isreal Deaconess Medical Center, Boston